June 14-20 is Men’s Health Week, and we are proud to be recognising the huge contributions our global team makes to the field of men’s health research. Our colleagues work tirelessly to further research, listening to the voices of those patients living with health issues that affect men disproportionately and ultimately allowing care pathways and treatments to be personalised, responsive, and …
June 6 is global National Cancer Survivors Day
It is a sad fact that cancer has – and likely will – touch all of our lives in some way. June 6 is global National Cancer Survivors Day. Our colleagues work tirelessly to further #oncology research, listening to the voices of those patients living with #cancer and ultimately allowing care pathways and treatments to be personalised, responsive, and effective.Here …
New research: Lenvatinib vs sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a phase 3 trial
Our CEO, Stacie Hudgens, is co-author of a manuscript published by The Lancet on June 1: Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trialHepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The …